World Immunotherapy Drugs Market to Grow 11.52% CAGR to 2020 says a New Research Report

Global Immunotherapy Drugs Market 2016-2020 - Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with Immunotherapy Drugs Market in subject line and your contact details.

Read 159 Pages Report at http://www.reportsnreports.com/reports/521060-globalimmunotherapy-drugs-2016-2020.html .

Immunotherapy enhances the innate powers of the immune system. The properties of the immune system to fight abnormal cells give immunotherapy drugs the chance of successfully fighting diseases such as cancer, respiratory, infectious, and autoimmune disorders.

The analysts forecast global immunotherapy drugs market to grow at a CAGR of 11.52% during the period 2016-2020.

Covered in this report The report covers the present scenario and the growth prospects of the global immunotherapy drugs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of immunotherapy drugs used to treat cancer, respiratory, infectious, autoimmune, and inflammatory diseases. It also considers the revenues to be generated from the sales of drugs, which are expected to be launched into the market, along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:   

Americas APAC EMEA

The report, Global Immunotherapy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Buy a copy of report @ http://www.reportsnreports.com/Purchase.aspx?name=521060 for US $2500.

Key vendors 

AbbVie Inc.

Global Immunotherapy Drugs Market 2016-2020

    

Amgen Inc. Bristol-Myers Squibb Company (BMS) F. Hoffmann-La Roche AG Johnson & Johnson Private Ltd. Merck & Co. Inc.

Other prominent vendors                                  

AB Science Ablynx Acorda Therapeutics ADC Therapeutics Aduro Biotech Advantagene Advaxis Agensys Inc. Agenus Inc. Alder Biopharmaceuticals AlphaVax Altor BioScience Antares Pharma Antigen Express Argos Therapeutics Inc. Astellas Pharma AstraZeneca AVAX Technologies Bavarian Nordic Baxter Bayer Biogen Biotech Pharmaceutical Biothera Boehringer Ingelheim Can-Fite BioPharma Celgene Celldex Therapeutics Celltrion Cel-Sci ChemoCentryx Chugai Pharmaceutical Coherus BioSciences CTI BioPharma

Global Immunotherapy Drugs Market 2016-2020

                                        

CureVac Cytos Biotachnology Daiichi Sankyo Eisai Eli Lilly Fortress Biotech Galena Biopharma Genexine Genmab Gilead Sciences GSK GlobeImmune Gradalis Heat Biologics Hospira Idera Immatics ImmunoCellular Therapeutics Immunomedics ImmuPharma Immutep Incyte Inovio Pharmaceuticals Intas Pharmaceuticals Invion ISA Pharmaceuticals Janssen Biotech Juvaris Biotherapeutics KaloBios Pharmaceuticals Kyowa Hakko Kirin Lexicon Pharmaceuticals MedImmune Morphotek Neovii Biotech Northwest Biotherapeutics Novartis NovaRx Novo Nordisk OncoMed Pharmaceuticals Oncothyreon Oncovir Inc.

Global Immunotherapy Drugs Market 2016-2020

                         

Opexa Therapeutics Inc. Oxford BioMedica Pfizer Prima BioMed Principia Progenics Provectus Biopharmaceuticals Regeneron Sandoz Sanofi Santarus Seattle Genetics Sotio Spectrum Pharmaceuticals Takeda TG Therapeutics Transgene UbiVac UCB Vaccinex Vaccinogen Vaxon Biotech Vertex Pharmaceuticals Vical Vitae Pharmaceuticals XBiotech

Inquire before Buying at http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=521060 .

Market driver 

Growing prevalence of cancer and autoimmune diseases

Market challenge 

Patent expiries of top-selling drugs

Market trend 

Increase in awareness programs

Global Immunotherapy Drugs Market 2016-2020

Key questions answered in this report 1.

2.

3.

4.

5.

6.

7.

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Inquire for Discount at http://www.reportsnreports.com/contacts/Discount.aspx?name=521060 .

List of Exhibits Exhibit 01: Product offerings Exhibit 02: Types of immunotherapy Exhibit 03: Key events in discovery and approvals of immunotherapy drugs Exhibit 04: Immunotherapy drugs approved by US FDA in 2015 Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs Exhibit 07: Phase III pipeline molecules for mAbs Exhibit 08: Phase II pipeline molecules for mAbs Exhibit 09: Phase I pipeline molecules for mAbs Exhibit 10: Pipeline molecules for immune checkpoint inhibitors Exhibit 11: Phase III pipeline molecules for vaccines Exhibit 12: Phase II pipeline molecules for vaccines Exhibit 13: Phase I pipeline molecules for vaccines Exhibit 14: Near-launch immuno-oncology pipeline assets Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions) Global Immunotherapy Drugs Market 2016-2020

Exhibit 16: Factors influencing global immunotherapy drugs market Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015 Exhibit 18: SWOT analysis of global immunotherapy drugs market Exhibit 19: Five forces analysis Exhibit 20: Market segmentation by type of immunotherapy drug Exhibit 21: Timeline of mAbs approval for cancer by US FDA Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA Exhibit 23: Global mAbs market 2015-2020 ($ billions) Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market Exhibit 25: Top vendor offerings in global mAbs market Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions) Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market Exhibit 29: Global vaccines market 2015-2020 ($ billions) Exhibit 30: Segmentation of global vaccines market by application 2015 Exhibit 31: Key drivers and challenges of global vaccines market Exhibit 32: Top vendor offerings in global vaccines market Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions) Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market Exhibit 35: Top vendor offerings in global non-specific immunotherapies market Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015

Global Immunotherapy Drugs Market 2016-2020

Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions) Exhibit 38: Global immunotherapy drugs market segmentation by therapy area Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015 Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015 Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions) Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions) Exhibit 43: Market share in the Americas by type of immunotherapy 2015 Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions) Exhibit 45: Market share in Europe by type of immunotherapy 2015 Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions) Exhibit 47: Market share in APAC by type of immunotherapy 2015 Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions) Exhibit 49: Global incidence of cancers 2015 and 2020 Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions) Exhibit 51: Patient assistance programs for immunotherapy drugs Exhibit 52: Some pipeline molecules for immunotherapy drugs Exhibit 53: Impact of drivers Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions) Exhibit 56: Impact of drivers and challenges

Global Immunotherapy Drugs Market 2016-2020

Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020 Exhibit 58: Market share analysis of top vendors0 Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)1 Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)1 Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 20152 Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 20152 Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions) Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)4 Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 20132015 ($ billions)5 Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155 Exhibit 67: F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 20156 Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)7 Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)8 Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)8 Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)8 Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 20132015 ($ millions)9 Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)0 Global Immunotherapy Drugs Market 2016-2020

Exhibit 74: F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)1 Exhibit 75: F. Hoffmann-La Roche: Key takeaways3 Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 20154 Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)5 Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)5 Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)5 Exhibit 80: AbbVie: Sales of HUMIRA in major markets 20156 Exhibit 81: AbbVie: Key takeaways7 Exhibit 82: Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 20158 Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 20158 Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)9 Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)0 Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)0 Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)0 Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 20122015 ($ billions)1 Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)1 Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)2 Exhibit 91: Johnson & Johnson: Key takeaways3 Exhibit 92: Merck: Business segmentation by revenue 20154 Global Immunotherapy Drugs Market 2016-2020

Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 20155 Exhibit 94: Merck: Top-selling immunotherapy drugs 20156 Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)7 Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)8 Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)8 Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)9 Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)9 Exhibit 100: Merck: Key takeaways2 Exhibit 101: Amgen: Top-selling immunotherapy drugs 20153 Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)4 Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)4 Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)4 Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)5 Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)5 Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)6 Exhibit 108: Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)6 Exhibit 109: Amgen: Key takeaways9 Exhibit 110: BMS: Business segmentation by revenue 20150 Exhibit 111: BMS: Immunotherapy drugs segmentation by revenue 20150 Exhibit 112: BMS: Top-selling immunotherapy drugs 20151

Global Immunotherapy Drugs Market 2016-2020

Exhibit 113: BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)2 Exhibit 114: BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)2 Exhibit 115: BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)3 Exhibit 116: BMS: Key takeaways Browse All Reports on Pharmaceuticals About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

Global Immunotherapy Drugs Market 2016-2020